SG11201506757TA - Halogenopyrazoles as inhibitors of thrombin - Google Patents
Halogenopyrazoles as inhibitors of thrombinInfo
- Publication number
- SG11201506757TA SG11201506757TA SG11201506757TA SG11201506757TA SG11201506757TA SG 11201506757T A SG11201506757T A SG 11201506757TA SG 11201506757T A SG11201506757T A SG 11201506757TA SG 11201506757T A SG11201506757T A SG 11201506757TA SG 11201506757T A SG11201506757T A SG 11201506757TA
- Authority
- SG
- Singapore
- Prior art keywords
- halogenopyrazoles
- thrombin
- inhibitors
- Prior art date
Links
- 108090000190 Thrombin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960004072 thrombin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789358P | 2013-03-15 | 2013-03-15 | |
| US201361899588P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/000058 WO2014149139A2 (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201506757TA true SG11201506757TA (en) | 2015-09-29 |
Family
ID=51538179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506757TA SG11201506757TA (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
| SG10201707486XA SG10201707486XA (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201707486XA SG10201707486XA (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9951025B2 (en) |
| EP (1) | EP2970141B1 (en) |
| JP (3) | JP6479749B2 (en) |
| KR (1) | KR20150130405A (en) |
| CN (2) | CN110423221A (en) |
| AU (2) | AU2014238478B2 (en) |
| BR (1) | BR112015023214A8 (en) |
| CA (1) | CA2902431A1 (en) |
| ES (1) | ES2791749T3 (en) |
| HK (1) | HK1214252A1 (en) |
| IL (1) | IL240763B (en) |
| MX (1) | MX373646B (en) |
| RU (1) | RU2015144193A (en) |
| SG (2) | SG11201506757TA (en) |
| WO (2) | WO2014149139A2 (en) |
| ZA (1) | ZA201506440B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678830C2 (en) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Multisubstituted aromatic compounds as serine protease inhibitors |
| KR20150130405A (en) | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | Halogenopyrazoles as inhibitors of thrombin |
| HK1246164A1 (en) | 2015-02-27 | 2018-09-07 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| KR20220004083A (en) | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | Solid form of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole |
| CN112062692A (en) * | 2019-06-11 | 2020-12-11 | 太仓市茜泾化工有限公司 | Preparation method of ethyl ethoxymethylene cyanoacetate |
| CN112986065B (en) * | 2021-02-08 | 2021-08-31 | 杭州同创医学检验实验室有限公司 | Whole blood quality control product for hematology analyzer and preparation method thereof |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US188918A (en) * | 1877-03-27 | Improvement in towel-racks | ||
| US1323438A (en) * | 1919-12-02 | of niagara falls | ||
| BE627394A (en) | 1962-01-23 | |||
| BE793955A (en) | 1972-01-15 | 1973-07-12 | Merck Patent Gmbh | ARYLPIPERAZINES AND THEIR PREPARATION PROCESS |
| DE2409753A1 (en) | 1974-03-01 | 1975-09-11 | Basf Ag | SUBSTITUTED PYRAZOLES |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
| PH23506A (en) | 1986-05-23 | 1989-08-16 | Smithkline Beckman Corp | 1-aralkyl-substituted-1,2,4,-triazole-5-thiols as dopamine- -hydroxylase inhibitors |
| JPH089541B2 (en) | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | Brain edema inhibitor containing pyrazoles as the main component |
| JP2784925B2 (en) * | 1988-09-07 | 1998-08-13 | 日本農薬株式会社 | 3 or 5-phenylpyrazoles or salts thereof and herbicides |
| ATE141502T1 (en) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | USE OF CARRAGEENAN IN TOPICAL OPHTHALMOLOGICAL COMPOSITIONS |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JP3810097B2 (en) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | Pyrrolidin-2-ylcarbonyl heterocyclic compound derivative |
| RO118291B1 (en) * | 1993-11-30 | 2003-04-30 | Searle & Co | PIRAZOL DERIVATIVES 1,3,4,5 - TETRASUBSTITUITIS AND PHARMACEUTICAL COMPOSITION CONTAINING CONTAINERS |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| US5733955A (en) | 1995-02-10 | 1998-03-31 | The Goodyear Tire & Rubber Company | Asphalt cement modification |
| JP3663522B2 (en) * | 1995-08-12 | 2005-06-22 | 日本農薬株式会社 | Composition for controlling plant growth and method of using the same |
| US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| US5739083A (en) | 1995-10-13 | 1998-04-14 | Otsuka Kagaku Kabushiki Kaisha | Pyrazole derivatives and insecticidal compositions containing the derivative as active component |
| AU713527B2 (en) * | 1996-08-12 | 1999-12-02 | Merck & Co., Inc. | Thrombin inhibitors |
| US5792761A (en) * | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
| DE19632773A1 (en) | 1996-08-14 | 1998-02-19 | Basf Ag | New thrombin inhibitors |
| GB9622370D0 (en) | 1996-10-28 | 1997-01-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| CZ225699A3 (en) | 1996-12-23 | 2000-09-13 | Du Pont Pharmaceuticals Company | Nitrogenous heteroaromatic compounds functioning as inhibitors of Xa factor |
| US6274536B1 (en) | 1997-03-21 | 2001-08-14 | Syngenta Crop Protection, Inc. | Pyrazole derivatives as herbicides |
| WO2000009500A2 (en) | 1998-08-11 | 2000-02-24 | Nihon Bayer Agrochem K.K. | Nematicidal pyrazoles |
| KR20000047461A (en) | 1998-12-29 | 2000-07-25 | 성재갑 | Thrombin inhibitors |
| SE9900070D0 (en) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| AR023510A1 (en) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR. |
| AU5020400A (en) * | 1999-05-20 | 2000-12-12 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| HUP0203542A3 (en) | 1999-08-12 | 2003-07-28 | Upjohn Co | 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| HUP0203954A2 (en) | 1999-09-17 | 2003-03-28 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor xa |
| RU2002117428A (en) | 1999-12-02 | 2003-12-20 | Новартис АГ (CH) | Aminoheterocyclamides as pesticides and antiparasitic agents |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| SI21097A (en) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Thrombine inhibitors |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| SE0200198D0 (en) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP2003313103A (en) * | 2002-02-20 | 2003-11-06 | Sankyo Agro Kk | Pesticides containing 4-acylaminopyrazole derivatives as active ingredients |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229070A1 (en) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenyl derivatives 5 |
| JP2006506340A (en) | 2002-08-09 | 2006-02-23 | アストラゼネカ アクチボラグ | Oxadiazole as a modulator of metabotropic glutamate receptor 5 |
| AU2003274025A1 (en) | 2002-10-17 | 2004-05-04 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| ATE444292T1 (en) | 2002-12-23 | 2009-10-15 | Sanofi Aventis Deutschland | PYRAZOLE DERIVATIVES AS FACTOR XA INHIBITORS |
| WO2004058722A1 (en) | 2002-12-24 | 2004-07-15 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| JP2004231528A (en) * | 2003-01-28 | 2004-08-19 | Sankyo Agro Kk | Amide derivatives |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004098518A2 (en) * | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
| CA2524269A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479679A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| EP1697342A2 (en) | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| EP1667983A4 (en) | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| KR101258504B1 (en) * | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | Inhibitors of histone deacetylase |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US8084451B2 (en) | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
| JPWO2006109846A1 (en) | 2005-04-06 | 2008-11-20 | 武田薬品工業株式会社 | Triazole derivatives and uses thereof |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| CN100427481C (en) | 2005-05-26 | 2008-10-22 | 沈阳化工研究院 | A kind of aryl ether compound and its preparation and application |
| WO2007067836A2 (en) | 2005-12-05 | 2007-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors |
| DE102006032824A1 (en) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituted indazoles |
| BRPI0715492A2 (en) | 2006-07-17 | 2013-03-19 | Boehringer Ingelheim Int | use of direct thrombin inhibitors |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
| EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008061796A2 (en) * | 2006-11-24 | 2008-05-29 | Ac Immune Sa | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2125778A1 (en) | 2006-12-22 | 2009-12-02 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| UY30892A1 (en) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
| WO2008105383A1 (en) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | Pyrazole derivative and use thereof for medical purposes |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| WO2009020137A1 (en) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | Aminopyrazole amide derivative |
| EP2196459B1 (en) | 2007-09-28 | 2016-11-02 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compound |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| CN101990433B (en) | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | Compounds that enhance atoh-1 expression |
| EP2300004A4 (en) | 2008-05-15 | 2012-05-30 | Univ Duke | COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS |
| CA2724430A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| CN102186809A (en) * | 2008-08-14 | 2011-09-14 | 拜尔农作物科学股份公司 | Insecticidal 4-phenyl-1h-pyrazoles |
| BRPI0917507A2 (en) | 2008-08-19 | 2015-11-17 | Boehring Ingelheim Internat Gmbh | dabigatran for interventional percutaneous cardiac caterization |
| EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| US20110306640A1 (en) | 2008-08-19 | 2011-12-15 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
| AR076753A1 (en) | 2009-05-07 | 2011-07-06 | Gruenenthal Chemie | DERIVATIVES OF CARBOXAMIDE AND UREA AROMATICS REPLACED AS LIGANDOS OF THE VANILLOID RECEIVER. |
| CN110269856A (en) * | 2010-03-30 | 2019-09-24 | 维颂公司 | Inhibitor of the polysubstituted aromatic compounds as fibrin ferment |
| CN101851207B (en) | 2010-06-11 | 2012-01-25 | 扬州康伊尔医药科技有限公司 | Antiviral compound intermediate 1-acyl-pyrazol-3-carboxylic acid and preparation method thereof |
| JPWO2012020820A1 (en) * | 2010-08-11 | 2013-10-28 | 大正製薬株式会社 | Heteroaryl-pyrazole derivatives |
| BR112013010320B8 (en) * | 2010-11-03 | 2022-10-11 | Dow Agrosciences Llc | PESTICIDE COMPOSITIONS. |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| AU2012255275B2 (en) | 2011-05-17 | 2016-01-28 | Plexxikon Inc. | Kinase modulation and indications therefor |
| US9371307B2 (en) | 2011-09-12 | 2016-06-21 | The Johns Hopkins University | Serine protease inhibitors |
| WO2013049591A2 (en) | 2011-09-29 | 2013-04-04 | Verseon Corporation | Dual inhibitor compounds and methods of use thereof |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| RU2678830C2 (en) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Multisubstituted aromatic compounds as serine protease inhibitors |
| KR20150130405A (en) * | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | Halogenopyrazoles as inhibitors of thrombin |
-
2014
- 2014-03-17 KR KR1020157027980A patent/KR20150130405A/en not_active Ceased
- 2014-03-17 MX MX2015011567A patent/MX373646B/en active IP Right Grant
- 2014-03-17 EP EP14769269.3A patent/EP2970141B1/en active Active
- 2014-03-17 CN CN201910623548.4A patent/CN110423221A/en active Pending
- 2014-03-17 CN CN201480027721.XA patent/CN105209440B/en active Active
- 2014-03-17 JP JP2016500154A patent/JP6479749B2/en active Active
- 2014-03-17 WO PCT/US2014/000058 patent/WO2014149139A2/en not_active Ceased
- 2014-03-17 SG SG11201506757TA patent/SG11201506757TA/en unknown
- 2014-03-17 HK HK16102083.6A patent/HK1214252A1/en unknown
- 2014-03-17 BR BR112015023214A patent/BR112015023214A8/en not_active IP Right Cessation
- 2014-03-17 SG SG10201707486XA patent/SG10201707486XA/en unknown
- 2014-03-17 RU RU2015144193A patent/RU2015144193A/en not_active Application Discontinuation
- 2014-03-17 AU AU2014238478A patent/AU2014238478B2/en active Active
- 2014-03-17 ES ES14769269T patent/ES2791749T3/en active Active
- 2014-03-17 CA CA2902431A patent/CA2902431A1/en not_active Abandoned
- 2014-03-17 US US14/776,641 patent/US9951025B2/en active Active
- 2014-03-18 WO PCT/US2014/030937 patent/WO2014146059A1/en not_active Ceased
-
2015
- 2015-08-23 IL IL24076315A patent/IL240763B/en not_active IP Right Cessation
- 2015-09-02 ZA ZA2015/06440A patent/ZA201506440B/en unknown
-
2018
- 2018-02-27 US US15/907,045 patent/US20180186751A1/en not_active Abandoned
- 2018-10-19 AU AU2018250514A patent/AU2018250514A1/en not_active Abandoned
-
2019
- 2019-02-06 JP JP2019019308A patent/JP2019081782A/en active Pending
-
2020
- 2020-06-16 JP JP2020103499A patent/JP2020158522A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014146059A1 (en) | 2014-09-18 |
| ZA201506440B (en) | 2019-06-26 |
| IL240763B (en) | 2019-11-28 |
| ES2791749T3 (en) | 2020-11-05 |
| CA2902431A1 (en) | 2014-09-25 |
| AU2014238478B2 (en) | 2018-07-19 |
| JP6479749B2 (en) | 2019-03-06 |
| HK1214252A1 (en) | 2016-07-22 |
| CN105209440B (en) | 2019-07-23 |
| EP2970141A2 (en) | 2016-01-20 |
| US20180186751A1 (en) | 2018-07-05 |
| WO2014149139A2 (en) | 2014-09-25 |
| JP2016512243A (en) | 2016-04-25 |
| SG10201707486XA (en) | 2017-10-30 |
| AU2018250514A1 (en) | 2018-11-15 |
| MX2015011567A (en) | 2016-04-25 |
| WO2014149139A3 (en) | 2014-11-27 |
| CN110423221A (en) | 2019-11-08 |
| JP2020158522A (en) | 2020-10-01 |
| CN105209440A (en) | 2015-12-30 |
| US20160046585A1 (en) | 2016-02-18 |
| EP2970141B1 (en) | 2020-02-26 |
| EP2970141A4 (en) | 2016-08-31 |
| US9951025B2 (en) | 2018-04-24 |
| MX373646B (en) | 2020-04-02 |
| IL240763A0 (en) | 2015-10-29 |
| AU2014238478A1 (en) | 2015-09-10 |
| KR20150130405A (en) | 2015-11-23 |
| RU2015144193A (en) | 2017-04-24 |
| BR112015023214A8 (en) | 2019-12-24 |
| BR112015023214A2 (en) | 2017-07-18 |
| JP2019081782A (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279682A (en) | Benzoquinolone inhibitors of vmat2 | |
| SI3305778T1 (en) | Inhibitors of plasma kallikrein | |
| PL3033336T3 (en) | Inhibitors of plasma kallikrein | |
| PL3057959T3 (en) | Dna-pk inhibitors | |
| EP2948450A4 (en) | Metalloenzyme inhibitor compounds | |
| SG11201507203RA (en) | Dna-pk inhibitors | |
| ZA201506156B (en) | Novel inhibitors | |
| EP3003372A4 (en) | Inhibitors of complement factor h | |
| IL245245A0 (en) | Novel dgat2 inhibitors | |
| IL246230A0 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| EP2994124A4 (en) | INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES | |
| ZA201506440B (en) | Halogenopyrazoles as inhibitors of thrombin | |
| IL244617A0 (en) | Benzoquinolone inhibitors of vmat2 | |
| PL2888228T3 (en) | Inhibitors of cd40-traf6 interaction | |
| ZA201508010B (en) | Inhibitors of metastasis | |
| GB201312311D0 (en) | Uses of enzyme inhibitors | |
| EP2959896A4 (en) | Inhibitor of tprotein phosphorylation | |
| GB201320835D0 (en) | HIF inhibitors |